The model
One person's whole-body cholesterol in days: the gut lumen, the liver, plasma LDL, the cholesterol in other tissues, and the bile acids that circulate between liver and gut. The liver senses its own cholesterol and adjusts four things within limits: how much it makes, how much the gut absorbs, how fast LDL is cleared, and how much cholesterol becomes bile acid. That feedback is why LDL moves less than the plate does, and why it takes weeks to settle.
- Rosuvastatin is taken up by the liver, which is where it blocks cholesterol synthesis. Lower synthesis makes the liver clear more LDL.
- Ezetimibe blocks absorption in the gut wall, and returns there with bile after each pass through the liver.
- Viscous fibre binds bile acids in the gut, so more leave with the stool and the liver spends cholesterol to replace them.
- The person is set by a reference: the LDL and the clearance rate they have on the usual plate, and how much of the gut's cholesterol they absorb (absorbers versus synthesisers). The model is calibrated so that this person is at steady state untreated.
LDL-years
Plaque grows with the LDL a vessel wall sees over years, so the page also shows the cumulative exposure: LDL times time, in mmol/L·years. The exposure above the reference is the extra (or saved) exposure compared with the person's own untreated level. A diet excursion is made up for when it returns to zero.
What this version does not do
- The drugs are given as a constant daily amount, not as tablets. The model's statin effect depends on how a dose is spread over the day much more than clinical experience suggests: the liver's statin level has too short a memory in this version. The statin potency is tuned for the constant-amount case.
- Saturated fat, exercise, triglycerides and HDL are not in the model yet.
- The model's response to dietary cholesterol is probably too strong; read the direction, not the size.